Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions ; volume:73 ; number:2 ; day:27 ; month:1 ; year:2024 ; pages:1-11 ; date:2.2024
Cancer immunology immunotherapy ; 73, Heft 2 (27.1.2024), 1-11, 2.2024
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
Li, Xingchen
Tian, Wenzhi
Jiang, Zhongxing
Song, Yongping
Leng, Xiangyang
Yu, Jifeng
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00262-023-03606-0
- URN
-
urn:nbn:de:101:1-2404291313398.699239761475
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Li, Xingchen
- Tian, Wenzhi
- Jiang, Zhongxing
- Song, Yongping
- Leng, Xiangyang
- Yu, Jifeng
- SpringerLink (Online service)
Ähnliche Objekte (12)
Normalization cancer immunotherapy: blocking Siglec-15!
Targeting TIGIT for cancer immunotherapy: recent advances and future directions
Targeting TNFR2 for cancer immunotherapy: recent advances and future directions
Nano‐LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec‐10 Signaling Pathway
Nano‐LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec‐10 Signaling Pathway
Targeting CD24 as a novel immunotherapy for solid cancers
Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions
Mesoporous Silica Nanoparticles as an Ideal Platform for Cancer Immunotherapy: Recent Advances and Future Directions.
Recent advances in cancer immunotherapy
Advances on immunotherapy for osteosarcoma
Recent advances in cancer immunotherapy
Recent advances in cancer immunotherapy
Normalization cancer immunotherapy: blocking Siglec-15!
Targeting TIGIT for cancer immunotherapy: recent advances and future directions
Targeting TNFR2 for cancer immunotherapy: recent advances and future directions
Nano‐LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec‐10 Signaling Pathway
Nano‐LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec‐10 Signaling Pathway
Targeting CD24 as a novel immunotherapy for solid cancers
Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions
Mesoporous Silica Nanoparticles as an Ideal Platform for Cancer Immunotherapy: Recent Advances and Future Directions.
Recent advances in cancer immunotherapy
Advances on immunotherapy for osteosarcoma
Recent advances in cancer immunotherapy
Recent advances in cancer immunotherapy
Normalization cancer immunotherapy: blocking Siglec-15!
Targeting TIGIT for cancer immunotherapy: recent advances and future directions
Targeting TNFR2 for cancer immunotherapy: recent advances and future directions
Nano‐LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec‐10 Signaling Pathway
Nano‐LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec‐10 Signaling Pathway
Targeting CD24 as a novel immunotherapy for solid cancers
Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions
Mesoporous Silica Nanoparticles as an Ideal Platform for Cancer Immunotherapy: Recent Advances and Future Directions.
Recent advances in cancer immunotherapy
Advances on immunotherapy for osteosarcoma
Recent advances in cancer immunotherapy